BOEHRINGER INGELHEIM AND ESTEVE ENTER INTO A JOINT PROMOTION AGREEMENT TO HELP PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION IN THE PREVENTION OF STROKE
Sant Cugat del Vallès (Barcelona) Boehringer Ingelheim and ESTEVE have reached an agreement after their first experience in respiratory care (undertaken with the same purpose and in the same year) whereby they enter into a joint promotion to share their commitment to improving the lives of patients with non-valvular atrial fibrillation (NVAF) at risk of suffering a stroke. The two companies will work together to promote two treatments from Boehringer Ingelheim using the only direct oral anticoagulant with rapid reversal. The agreement involves simultaneously promoting two treatments from the German pharmaceutical company.
The two managing directors concurred: "It's a great opportunity". Timmo Andersen, Managing Director of Boehringer Ingelheim Spain, emphasized that "this agreement represents a collective challenge and is yet another demonstration of innovation, commitment and value by the two companies, always bearing in mind the benefit this has in patients with cardiovascular diseases".
In the words of Joseph Sullivan, Managing Director of ESTEVE Farma, "By placing its trust in our company again, Boehringer Ingelheim's helps us keep securing a wide range of solutions to help professionals better manage patient problems as well as to provide response to unmet medical needs."
ESTEVE (www.esteve.com) is a leading chemical-pharmaceutical group in Spain with a strong international presence. Founded in 1929 and presided over by Joan Esteve, the Company currently employs 2,279 people, has a presence in Europe, USA, Mexico and China, and had a sales revenue of 870 million Euros in 2015.
ESTEVE is firmly committed to excellence and uses its best efforts to promote health and improve people's quality of life. Research being ESTEVE's hallmark, a portfolio of highly innovative projects ultimately aims to provide response to unmet medical needs. Because ESTEVE is a socially responsible Company, it ensures that all projects entered by it align with its CSR vision.
Boehringer Ingelheim "Value through innovation"The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 subsidiaries and more than 47,500 employees. The focus of this family owned company, founded in 1885, is researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine.
Social responsibility is an important element of the corporate culture at Boehringer Ingelheim. This includes worldwide involvement in social projects, such as the initiative "Making more Health", and caring for its employees and their families. Respect, equal opportunities and reconciling work and family life form the foundation of mutual cooperation. In everything it does, the company focuses on environmental protection and sustainability.
Boehringer Ingelheim has been in Spain since 1952, a 60+ year evolution that has made it one of the top 15 companies in the pharmaceutical sector of our country. With Spanish headquarters located in Sant Cugat del Vallès, it currently has over 1,600 employees and two international production facilities in Sant Cugat del Vallès and Malgrat de Mar.
You can follow ESTEVE on Twitter at this link:
ESTEVE APPOINTS JORDI MUNTAÑOLA AS CHIEF COMMERCIAL OFFICER FOR EUROPE
Jordi Muntañola will take on the leadership of all the pharmaceutical activities in Spain and Europeread more
POMPEU FABRA UNIVERSITY AND ESTEVE ARE TO INVESTIGATE NEW TARGETS FOR TREATING NEUROPATHIC PAIN
The RIBOPAIN project aims to identify new therapeutic solutions for pain and to develop more effective drugsread more
ESTEVE ANNOUNCES A RESTRUCTURING OF ITS PHARMACEUTICAL ACTIVITY
Esteve Pharmaceuticals submits a reduction in force (RIF) which will affect 103 jobs in Spainread more